1.
wcrf.org/int/cancer-facts-figures/data-specific-cancers/pancreatic-cancer-statistics
2.
Rahib L,
Smith BD,
Aizenberg R,
Rosenzweig AB,
Fleshman JM,
Matrisian LM.
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid,
liver,
and pancreas cancers in the United States.
Cancer Res.
2014 Jun
1;74(11):2913-21.
3.
Hidalgo M.
Pancreatic cancer.
New Engl J Med.
2010;362:1605–1617.
4.
Ferrone CR,
Pieretti-VanmarckeR,
Bloom JP,
et al.
Pancreatic ductal adenocarcinoma: long-term survival does not equal cure.
Surgery.
2012;152:S43–S49.
5.
Sa Cunha A,
Rault A,
Laurent C,
Adhoute X,
Vendrely V,
Béllannée G,
et al.
Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas.
J Am Coll Surg.
2005 Sep;201(3):359-65.
6.
Gillen S,
Schuster T,
Meyer Zum Buschenfelde C,
et al.
Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and metaanalysis of response and resection percentages.
PLoS Med.
2010;7:e1000267.
7.
Conroy T,
Desseigne F,
Ychou M,
Bouché O,
Guimbaud R,
Bécouarn Y,
et al.
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
N Engl J Med.
2011 May 12;364(19):1817-25.
8.
Therasse P,
Arbuck SG,
Eisenhauer EA,
et al.
New guidelines to evaluate the response to treatment in solid tumors.
European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States,
National Cancer Institute of Canada.
J Natl Cancer Inst 2000;92(3):205–216.
9.
Eisenhauer EA,
Therasse P,
Bogaerts J,
et al.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eur J Cancer 2009;45(2):228–247.
10.
Ferrone CR,
Marchegiani G,
Hong TS,
Ryan DP,
Deshpande V,
McDonnell EI,
et al.
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
Ann Surg.
2015 Jan;261(1):12-7.
11.
Choi H,
Charnsangavej C,
Faria SC,
et al.
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
J Clin Oncol 007;25(13):1753-1759.
12.
Cassinotto C,
Mouries A,
Lafourcade JP,
Terrebonne E,
Belleannée G,
Blanc JF,
et al.Radiology.
2014 Oct;273(1):108-16.
13.
Wahl RL,
Jacene H,
Kasamon Y,
Lodge MA.
From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors.
J Nucl Med 2009;50(suppl 1):122S–150S.
14.
Padhani AR,
Liu G,
Koh DM,
et al.
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.
Neoplasia 2009;11(2)102-125.
15.
Richard KG – mskcc.org/clinical-updates - April 2015.